Navigation Links
Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management

BURLINGTON, Mass., July 7, 2015 /PRNewswire/ -- Decision Resources Group finds that there are similarities and differences in dialysis patient management in the U.S. versus the EU5. In 2015, based on information submitted by U.S. and EU5 nephrologists from approximately 1,870 dialysis patient charts combined, ESAs and phosphate binders are the most commonly used renal medications in dialysis patients; however, the use of IV iron differs considerably between the two regions.     

Other key findings from the ChartTrends reports entitled Nephrology in Dialysis (US) 2015 and Nephrology in Dialysis (EU5) 2015:

  • Hemoglobin at ESA Initiation: In the U.S. and the EU5, physicians report a higher mean hemoglobin at ESA initiation versus the audited patient charts. However, the audited hemoglobin at ESA initiation is lower in the U.S. compared with the EU5. These reports also cover phosphorus at phosphate binder initiation, hemoglobin, ferritin and transferrin saturation (TSAT) at IV iron initiation, parathyroid hormone (PTH) at Amgen's Sensipar/Mimpara initiation, as well as other laboratory parameters at treatment initiation.
  • IV Iron Discontinuation Rates: Chart audits indicate that a low percentage of dialysis patients were discontinued from IV iron; the more common reasons for discontinuation include completion of repletion course and ferritin/TSAT level. In addition, higher rates of IV iron discontinuation exist in the U.S. than in the EU5. This may be one of many reasons for higher rates of oral iron use in the U.S. These reports also cover ESAs, phosphate binders, nutritional Vitamin D, active Vitamin D and Amgen's Sensipar/Mimpara discontinuation rates as well.
  • Dialysis Patient Characteristics: The percentage of dialysis patients that have had a blood transfusion in the past year is one characteristic in particular where there were large differences between the U.S. and the EU5. Several questions related to patient demographics are included such as age, gender, location of their dialysis, hospitalization rates, reason for recent hospital admission, co-morbidities, primary cause of renal disease, hemoglobin level at time of blood transfusion, calcification, monthly laboratory parameters for hemoglobin, TSAT, ferritin, phosphorous, calcium, PTH, and potassium among other characteristics. These demographics allow manufactures to see differences between treated and non-treated patients. 
  • Potential Use of Emerging Therapies: Physicians reviewed product profiles of various emerging therapies and were asked whether a particular patient would be started on this therapy now (assuming regulatory approval). This methodology allows manufactures to see a potential percentage for use and patient profiles that includes critical information such as relevant laboratory values for treatment initiation.

Comments from Decision Resources Group Director Rob Dubman:

  • "This is now the fourth U.S. ChartTrends report focused on dialysis patient management since the implementation of dialysis bundle, which we believe led to additional scrutiny and awareness of the total costs of treatment. In 2015, in the U.S., there has been a stabilization of the historical decline in the use of ESAs as well as lower mean hemoglobin levels at most recent measure. However, the increase in blood transfusion rates is a concerning phenomenon."

For more information on purchasing these reports, please email

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 700 employees across 15 global locations. DRG companies provide the pharmaceutical, biotech, medical device, financial services and payer industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace.

Media contact:
SHIFT Communications
Rosie Hale

Logo -

SOURCE Decision Resources Group
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach
2. Differences Over Pathways Developed by Oncologists and MCOs May Create Conflict Over Prescribing Decisions in Early-Line Treatment
3. International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments
4. iMD announces refocus on existing Hydroponic Lighting product lines
5. Saratoga Hospital Selects Omnicell Unity Enterprise Platform to Upgrade Existing Medication Automation Solutions
6. Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers
7. Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
8. Chiltern Announces The Consolidation Of Existing Investor Base
9. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
10. Several Market Access Barriers Impede Multinational Companies From Easily Accessing Argentinas Pharmaceutical Market But Attractive Opportunities Exist
11. Anesthesiologist Survey Suggests Existing Pulse Oximetry Sensors Unreliable; Most Physicians Need Multiple Sensors in Surgery
Post Your Comments:
(Date:9/22/2019)... (PRWEB) , ... September 22, 2019 , ... ... Bellevue, WA offering the highest level of both plastic surgery and non-surgical aesthetic ... FDA-cleared microneedling device. Microneedling is a proven skin rejuvenation treatment that uses tiny ...
(Date:9/18/2019)... WASHINGTON, Pa. (PRWEB) , ... ... ... Inc. (USH), parent organization to ReachMD, Global Learning Collaborative, and other healthcare-focused ... digital learning environment, DecisionSimâ„¢, uses real-world cases to challenge healthcare professionals (HCPs) ...
(Date:9/17/2019)... (PRWEB) , ... September 18, 2019 , ... Uniform ... Beyond Breast Cancer to raise funds for Breast Cancer programs and services. , This ... 42,000 will die of the disease. During the month of October 2019, Uniform Advantage ...
Breaking Medicine Technology:
(Date:9/18/2019)... ... , ... A new study by BestPlaces looks at ten indicators to produce the first ranking ... so other related rights vary widely across the 50 states. , Ten topics ... orientation) , Employment , Education , Gender Marker Updates ...
(Date:9/17/2019)... ... 17, 2019 , ... Since the registration of the NociScan ... in the US, Nocimed has been marketing its unique technology to healthcare clinicians ... MRI equipment to perform MR spectroscopy, NociScan detects the presence of chemical biomarkers ...
(Date:9/17/2019)... N.Y. (PRWEB) , ... September 17, 2019 , ... ... medicine cabinet could help extend the lives of some cancer patients? In companion ... Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose ...
(Date:9/17/2019)... ... 17, 2019 , ... The Center for Information and Study ... third edition of The Gift of Participation. Written by CISCRP Founder, Ken Getz, ... navigate the clinical research process. The new edition offers a fresh look at ...
(Date:9/12/2019)... (PRWEB) , ... September 12, 2019 , ... ... both a local and national scale in two recent and well-renowned listing publications, ... fastest-growing privately held businesses for the 2019 year. , Dr. Jeffrey Donaldson, ...
Breaking Medicine News(10 mins):